Drugs / ALACIZUMAB PEGOL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00152477 | Aug 2005 → Jun 2009 | non-small cell lung carcinoma | UCB Pharma | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALACIZUMAB PEGOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742983 ↗ |
| Known as | CDP791 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00152477 ↗ |
| Known as | g165 DFM-PEG | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742983 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 antagonist” CHEMBL1742983 ↗ |
| Modality | Monoclonal antibody | — CHEMBL1742983 ↗ |
| Route | Intravenous | “will be given as a 200mL iv infusion over approximately 60 minutes” NCT00152477 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 antagonist” CHEMBL1742983 ↗ |